Copyright © 2002 by the European Society of Cardiology.
Frequency and long-term impact of myonecrosis after coronary stenting
Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, U.S.A.
revised August 14, 2001; accepted August 15, 2001
Abstract
Aims To study the frequency of creatine kinase MB elevation in stent recipients and to correlate the magnitude of myonecrosis with long-term ischaemic events.
Methods and Results We evaluated the frequency and impact (major adverse ischaemic events) of creatine kinase MB elevation in 3478 patients undergoing planned coronary stenting and divided them in five strata according to peak creatine kinase MB: normal, 1–3x, 3–5x, 5–10x and >10x above upper limit of normal. Graft intervention was done in 15% and 61% received platelet glycoprotein IIb/IIIa receptor inhibitors. The average follow-up period was 15±15 (range 1–72) months. Creatine kinase MB elevation above upper limit of normal occurred in 24% and in 5·3% it was greater than 5xupper limit of normal. The unadjusted rates of actuarial mortality in the five strata were: 7·5% (198/2637), 8·0% (40/502), 11·0% (17/155), 10·8% (11/102) and 29·3% (24/82), respectively, P<0·001. Logistic regression analysis including 18 demographic and procedural variables revealed that, in addition to age, extent of coronary disease, ventricular function and coronary risk profile, creatine kinase MB elevation was associated with a significant increase in major ischaemic events at follow-up. The excess risk was concentrated mainly in the highest stratum of creatine kinase MB elevation.
Conclusions Thus, in the era of stenting and aggressive adjunctive pharmacology, peri-procedural myonecrosis still remains frequent and has an important impact on long-term event-free survival. Intensive efforts to reduce creatine kinase MB elevation after revascularization are warranted and should lead to important benefits. Copyright 2001 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved
Key Words: Angioplasty, long-term follow-up, stent, creatine kinase MB
f1 Correspondence: Sorin J. Brener MD, FACC, 9500 Euclid Ave., Desk F-25, Cleveland, Ohio, 44195, U.S.A.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Y. Wang, E. D. Peterson, D. Dai, H. V. Anderson, S. V. Rao, R. G. Brindis, M. T. Roe, and on behalf of the National Cardiovascular Data Regi Patterns of Cardiac Marker Surveillance After Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: A Report From the National Cardiovascular Data Registry (NCDR). J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2068 - 2074. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nusca, R. Melfi, and G. Di Sciascio Review: Percutaneous coronary interventions and statins therapy Therapeutic Advances in Cardiovascular Disease, April 1, 2008; 2(2): 101 - 107. [Abstract] [PDF]
|
|
|
|
 |
|
 C.-H. Lee, A. Low, B.-C. Tai, M. Co, M. Y. Chan, J. Lim, Y.-T. Lim, and H.-C. Tan Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study Eur. Heart J., January 1, 2007; 28(1): 19 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Bahrmann, H R Figulla, M Wagner, M Ferrari, A Voss, and G S Werner Detection of coronary microembolisation by Doppler ultrasound during percutaneous coronary interventions Heart, September 1, 2005; 91(9): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-K Wong and H D White Implications of the new definition of myocardial infarction Postgrad. Med. J., September 1, 2005; 81(959): 552 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cavallini, S. Savonitto, R. Violini, G. Arraiz, M. Plebani, Z. Olivari, P. Rubartelli, S. Battaglia, L. Niccoli, G. Steffenino, et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study Eur. Heart J., August 1, 2005; 26(15): 1494 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Claeys, M. G. Van der Planken, J. M. Bosmans, J. J. Michiels, F. Vertessen, P. Van Der Goten, F. L. Wuyts, and C. J. Vrints Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis Eur. Heart J., March 2, 2005; 26(6): 567 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Nathoe, E. Buskens, E. W.L. Jansen, W. J.L. Suyker, P. R. Stella, J. R. Lahpor, W.-J. van Boven, D. van Dijk, J. C. Diephuis, C. Borst, et al. Role of Coronary Collaterals in Off-Pump and On-Pump Coronary Bypass Surgery Circulation, September 28, 2004; 110(13): 1738 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, G. Di Sciascio, and on behalf of the ARMYDA Investigators Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study Circulation, August 10, 2004; 110(6): 674 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K French and H. D White Clinical implications of the new definition of myocardial infarction Heart, January 1, 2004; 90(1): 99 - 106. [Full Text] [PDF]
|
|
|
|
|
|
J. P. A. Ioannidis, E. Karvouni, and D. G. Katritsis Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1406 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lemos, C.-h. Lee, M. Degertekin, F. Saia, K. Tanabe, C. A. Arampatzis, A. Hoye, M. van Duuren, G. Sianos, P. C. Smits, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: Insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2093 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colombo and G. Stankovic Nothing is lower than 0, and 3 is closer to 0 than to 5--medicine is not arithmetic Eur. Heart J., June 1, 2002; 23(11): 840 - 842. [Full Text] [PDF]
|
|